Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08653944 Relative Bioavailability Across Injection Sites in Overweight/Obese Adults
NCT07400679Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2026
- Primary completion
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF-08653944 in obesity (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration Versus Time Curve at 85 days and Maximum Observed Concentration at 85 days. Started Feb 2026; status: completed.
02
Drugs
PF-08653944
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07400679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400679.